EyePoint, Inc.
DE ˙ DB ˙ US30233G2093
10,10 € ↓ -0,30 (-2,88%)
2026-06-04
AKTIENPREIS
SecurityDE:PV3B / EyePoint, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership140,726 shares
Latest Disclosed Value $ 2,571,064
Barclays Plc ownership in PV3B / EyePoint, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 140,726 shares of EyePoint, Inc. (DE:PV3B) valued at $2,129,184 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 103,703 shares of EyePoint, Inc.. This represents a change in shares of 35.70% during the quarter. The current value of the position is $1,421,333 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (PV3B) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:PV3B / EyePoint, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F EYEPOINT COM 30233G209 140,726 37,023 35.70 2,571 74.19 0.0006
2026-03-31 2025-09-30 13F/A-3 EYEPOINT PHARMACEUTICALS COM 30233G209 103,703 -19,604 -15.90 1,477 27.24 0.0003
2026-03-19 2025-09-30 13F/A-2 EYEPOINT PHARMACEUTICALS COM 30233G209 245,045 121,738 1,958 0.0005
2025-11-12 2025-09-30 13F EYEPOINT PHARMACEUTICALS COM 30233G209 103,703 -19,604 1,477 0.0003
2026-02-27 2025-06-30 13F/A-2 EYEPOINT PHARMACEUTICALS COM 30233G209 123,307 24,282 24.52 1,160 116.42 0.0003
2025-08-14 2025-06-30 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 123,307 24,282 1 0.0003
2025-08-13 2025-06-30 13F EYEPOINT PHARMACEUTICALS COM 30233G209 123,307 24,282 1 0.0001
2026-03-17 2025-03-31 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 99,025 -21,196 -17.63 537 -40.11 0.0002
2025-05-15 2025-03-31 13F EYEPOINT PHARMACEUTICALS COM 30233G209 99,025 -21,196 1 0.0002
2026-03-19 2024-12-31 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 120,221 -124,824 -50.94 896 -54.27 0.0003
2025-02-13 2024-12-31 13F EYEPOINT PHARMACEUTICALS COM 30233G209 120,221 -124,824 1 0.0003
2026-03-31 2024-09-30 13F/A-2 EYEPOINT PHARMACEUTICALS COM 30233G209 245,045 197,033 410.38 1,958 369.30 0.0005
2024-11-19 2024-09-30 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 245,045 197,033 2 0.0005
2024-11-15 2024-09-30 13F EYEPOINT PHARMACEUTICALS COM 30233G209 245,045 197,033 2 0.0002
2026-03-23 2024-06-30 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 48,012 -117,675 -71.02 418 -87.82 0.0001
2024-08-14 2024-06-30 13F EYEPOINT PHARMACEUTICALS COM 30233G209 48,012 -117,675 0 0.0001
2026-03-24 2024-03-31 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 165,687 6,045 3.79 3,425 -7.18 0.0012
2024-05-15 2024-03-31 13F EYEPOINT PHARMACEUTICALS COM 30233G209 165,687 6,045 3 0.0012
2026-03-25 2023-12-31 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 159,642 113,983 249.64 3,689 913.46 0.0014
2024-02-15 2023-12-31 13F EYEPOINT PHARMACEUTICALS COM 30233G209 159,642 113,983 4 0.0014
2026-03-26 2023-09-30 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 45,659 23,208 103.37 365 86.67 0.0002
2023-11-07 2023-09-30 13F EYEPOINT PHARMACEUTICALS COM 30233G209 45,659 23,208 0 0.0002
2026-03-30 2023-06-30 13F/A-2 EYEPOINT PHARMACEUTICALS COM 30233G209 22,451 -5,523 -19.74 195 137.80 0.0001
2023-09-20 2023-06-30 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 22,451 -5,523 0 0.0001
2023-08-03 2023-06-30 13F EYEPOINT PHARMACEUTICALS COM 30233G209 22,451 -5,523 0 0.0001
2026-03-30 2023-03-31 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 27,974 20,969 299.34 82 241.67 0.0000
2023-05-04 2023-03-31 13F EYEPOINT PHARMACEUTICALS COM 30233G209 27,974 20,969 0 0.0000
2026-03-30 2022-12-31 13F/A-1 EYEPOINT PHARMACEUTICALS COM 30233G209 7,005 5,899 533.36 25 166.67 0.0000
2023-02-13 2022-12-31 13F EYEPOINT PHARMACEUTICALS COM 30233G209 7,005 5,899 0 0.0000
2022-11-03 2022-09-30 13F EYEPOINT PHARMACEUTICALS COM 30233G209 1,106 -203 -15.51 9 -10.00 0.0000
2022-08-12 2022-06-30 13F EYEPOINT PHARMACEUTICALS COM 30233G209 1,309 -2,737 -67.65 10 -79.59 0.0000
2022-05-16 2022-03-31 13F EYEPOINT PHARMACEUTICALS COM 30233G209 4,046 4,046 49 0.0000
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-03-23 2024-06-30 13F/A EYEPOINT PHARMACEUTICALS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F EYEPOINT PHARMACEUTICALS OPT Put 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A EYEPOINT PHARMACEUTICALS OPT Put 134,000 2,770 n/a n/a n/a
2024-05-15 2024-03-31 13F EYEPOINT PHARMACEUTICALS OPT Put 134,000 3 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.